Laura Shawver - 01 Feb 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role: Chief Executive Officer, Director
Signature: /s/ Jeffrey C. Pepe, Attorney-in-Fact
Issuer symbol: SPRY
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2022, 16:17:10 UTC
Previous filing: 15 Jun 2021
Next filing: 04 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SPRY	Common Stock	Award	$0	+27,500	+34%	$0.000000	107,395	01 Feb 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SPRY	Stock Option (right to buy)	Award	$0	+165,000		$0.000000	165,000	01 Feb 2022	Common Stock	165,000	$4.85	Direct	F3
transaction	SPRY	Stock Option (right to buy)	Award	$0	+104,500		$0.000000	104,500	01 Feb 2022	Common Stock	104,500	$4.85	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 682 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021.
F3	The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
F4	25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.